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The interaction of an MHC–peptide complex 
with a TCR on CD8+ CTL is a crucial step 
toward the activation of virus-specifi  c T cell 
responses (for review see references 1, 2). Pep-
tide epitopes bound to MHC molecules are 
derived from viral proteins synthesized within 
the infected cells, which determine the speci-
fi  city of the interaction between the TCR and 
MHC molecules (3). It is now fi  rmly estab-
lished that CTL recognition of virus-infected 
cells is dependent on the intracellular degra-
dation of virally encoded proteins so that 
suffi     cient MHC–peptide complexes can be 
generated (4–6). In addition to intracellular 
degradation, the steady-state concentration of 
viral proteins and effi   ciency of endogenous pro-
cessing also determine epitope production (7). 
Indeed, the importance of these crucial steps 
in the generation of MHC–peptide complexes 
is highlighted by the fact that pretreatment of 
virus-infected cells with proteasome inhibitors 
(e.g., lactacystin) blocks the endogenous pro-
cessing of peptide epitopes resulting in inhibi-
tion of T cell recognition (8–10).
A major caveat of the above concept is that 
the majority of antigenic peptides are derived 
from viral proteins, which are extremely stable. 
A classic example of one such protein is the 
EBV-encoded nuclear antigen 1 (EBNA1), 
which not only inhibits its self-synthesis but also 
blocks its proteasomal degradation (11, 12). Re-
cent studies from our laboratory and others have 
shown that in spite of the highly stable nature of 
this protein in B cells, immunodominant epi-
topes can be effi   ciently generated (13–15). An 
extensive analysis of the endogenous processing 
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A signifi  cant proportion of endogenously processed CD8+ T cell epitopes are derived from 
newly synthesized proteins and rapidly degrading polypeptides (RDPs). It has been hypothe-
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these RDP precursors may be infl  uenced by the effi  ciency of protein translation. Here we 
address this hypothesis by using the Epstein-Barr virus–encoded nuclear antigen 1 protein 
(EBNA1), with or without its internal glycine-alanine repeat sequence (EBNA1 and 
EBNA1𝖫GA, respectively), which display distinct differences in translation effi  ciency. We 
demonstrate that RDPs constitute a signifi  cant proportion of newly synthesized EBNA1 and 
EBNA1𝖫GA and that the levels of RDPs produced by each of these proteins directly corre-
late with the translation effi  ciency of either EBNA1 or EBNA1𝖫GA. As a consequence, a 
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the surface of cells expressing EBNA1𝖫GA, and these cells are more effi  ciently recognized 
by virus-specifi  c cytotoxic T lymphocytes compared to the full-length EBNA1. More impor-
tantly, we also demonstrate that the endogenous processing of these CD8+ T cell epitopes 
is predominantly determined by the rate at which the RDPs are generated rather than the 
intracellular turnover of these proteins.
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of EBNA1 revealed that antigenic epitopes from this protein 
are not necessarily derived from the degradation of the full-
length stable protein, but rather are processed from newly syn-
thesized polypeptides which are rapidly degraded (13, 14). 
These observations were consistent with the defective ribo-
somal products (DRiPs) hypothesis proposed by Yewdell et al. 
(16, 17). Studies performed by these authors have shown that 
about one-third of newly synthesized proteins are degraded 
within 15 min after expression and peptide-dependent matu-
ration of class I molecules in the endoplasmic reticulum can be 
signifi  cantly blocked when protein translation is suppressed 
with protein synthesis inhibitors (10, 18).
More importantly, there is now suffi   cient evidence to 
  indicate that a substantial proportion of MHC class I–peptide 
complexes are derived from proteins that are expressed and 
degraded within very short periods (i.e., <2 h) (10). Collec-
tively, these observations strongly suggest that protein trans-
lation effi   ciency may play a crucial role in determining the 
effi   ciency by which MHC–peptide complexes are generated 
endogenously. To test this hypothesis we have compared the 
endogenous presentation of CD8+ T cell epitopes from the 
EBV-encoded EBNA1 protein with and without its internal 
glycine-alanine repeat, which display distinct diff  erences in 
translation effi   ciency (19). Our analysis showed that the trans-
lation effi   ciency of these proteins directly correlated with 
the effi   ciency by which the rapidly degrading polypeptides 
are generated and consequently eff  ects the presentation of 
MHC–peptide complexes on the cell surface and immune 
recognition by virus-specifi  c T cells.
RESULTS
Detection of EBNA1-specifi  c rapidly degrading polypeptides
Previous studies have shown that in spite of a cis-inhibitory 
eff  ect of the GAr domain on the translation of EBV-encoded 
EBNA1 (11), CD8+ T cell epitopes from this protein can be 
effi   ciently generated and presented on the surface of virus-
infected cells (13–15). Extensive analysis of endogenous pro-
cessing revealed that most of these epitopes were derived 
from newly synthesized protein rather than long-lived pools 
of EBNA1 protein. It was hypothesized that DRiPs, which 
are by-products of rapidly degrading polypeptides (RDPs) of 
newly synthesized EBNA1 protein, may constitute a major 
source of these epitopes (13). To provide proof of this hy-
pothesis, we transfected HeLa cells with expression vectors 
  encoding GFP-tagged EBNA1 with or without the GAr domain 
(referred to as EBNA1-GFP and EBNA1∆GA-GFP). These 
cells were left untreated or pretreated with 50 μM of the 
proteasome inhibitors MG132 and lactacystin during the fi  nal 
30 min of a 60-min starvation in Met-free medium preceding 
a short [35S]methionine pulse (2 min) and chase (10, 18). GFP 
immunoprecipitates from the lysed extracts were analyzed by 
SDS-PAGE (Fig. 1 A). These experiments showed two im-
portant observations. First, newly synthesized EBNA1-GFP 
and EBNA1∆GA-GFP showed a smear of protein bands 
ranging from 120 to 40 kD, and the intensity of these bands 
was relatively stronger in cells expressing EBNA1∆GA-GFP. 
Second, a more rapid degradation of these polypeptides was 
observed in cells not treated with proteasome inhibitors. In 
contrast, pretreatment of the transfectants with MG132 and 
lactacystin blocked the degradation of these polypeptides. 
Figure 1.  EBNA1 and EBNA1∆GA translation effi  ciency and rap-
idly degrading polypeptides. (A) Detection of EBNA1 rapidly degrading 
polypeptides. HeLa cells treated with 50 μM of both MG132 and lactacys-
tin during the fi  nal 30 min of a 60-min starvation in Met-free media were 
radiolabeled for 2 min and chased for 5 min. EBNA1-GFP immunoprecipi-
tates were subjected to SDS-PAGE and autoradiograpy. Mol wt markers in 
kD are shown on the left. Arrows indicate full-length EBNA1-GFP and 
EBNA1∆GA-GFP. (B) Measurement of EBNA1 synthesis. HEK293 cells 
transfected with either EBNA1-GFP or EBNA1∆GA-GFP were metabolically 
labeled for 12–14 h in growth medium containing 20 μCi/ml of [3H]methionine 
followed by a 30-min pulse with 100 μCi of [35S]methionine. Cells were 
lysed and immunoprecipitated with either anti-GFP or antitubulin. Quan-
titation of EBNA1-GFP, EBNA1∆GA-GFP, or tubulin synthesis was deter-
mined by measuring the [35S] to [3H] ratio for each protein by liquid 
scintillation counting. (C) In vitro translation assay of EBNA1 and EBNA1∆GA. 
pcDNA3.1 expression constructs encoding either EBNA1 or EBNA1∆GA 
were transcribed and translated in vitro with T7 RNA polymerase using a 
coupled transcription–translation reticulocyte lysate system supplemented 
with [35S]methionine. Band intensities were quantifi  ed by densitometric 
analysis of the imaging data and graphed.JEM VOL. 204, March 19, 2007  527
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No GFP-specifi  c protein bands were observed under similar 
conditions from mock-transfected cells (Fig. 1 A). These obser-
vations strongly suggest that the observed polypeptide smears 
represent EBNA1-specifi  c RDPs and not cellular proteins 
binding nonspecifi  cally to anti-GFP immunocomplexes.
To further explore the diff  erence in the translation effi   -
ciencies of EBNA1 and EBNA1∆GA, we measured absolute 
rates of synthesis relative to a common standard protein using 
a double label protocol (20). HEK293 cells were transfected 
with expression vectors encoding either EBNA1-GFP or 
EBNA1∆GA-GFP, and 24 h after transfection the cells were 
labeled with a low concentration of [3H]methionine (12–14 h), 
followed by a short pulse (30 min) with [35S]methionine. The 
amount of tritium label per cell serves as the standard against 
which to measure the effi   cacy of incorporation during the 
pulse. By examining the ratio of label for a standard protein by 
immunoprecipitation (e.g., tubulin), we estimated the rates of 
synthesis for EBNA1-GFP and EBNA1∆GA-GFP. Total in-
corporation of [35S]methionine during the pulse relative to 
the total amount of [3H]methionine allowed us to  determine 
whether EBNA1∆GA-GFP was synthesized at a rate greater, 
equal, or less than the full-length EBNA1-GFP. Representa-
tive data from one of these experiments is presented in Fig. 1 B. 
As expected, the rate of synthesis for   tubulin was very 
similar in HEK293 cells transfected with expression vectors 
encoding EBNA1-GFP or EBNA1∆GA-GFP. In contrast, 
the rate of synthesis for EBNA1∆GA-GFP was 3.7 times 
higher compared with full-length EBNA1-GFP. These obser-
vations were further supported by an in vitro translation assay 
that demonstrated increased translation of EBNA1∆GA com-
pared with EBNA1 (Fig. 1 C). These experi  ments collectively 
provide strong evidence that a substantial fraction of newly syn-
thesized EBNA1 protein is composed of RDPs and that the 
deletion of the GAr domain domain dramatically increases the 
translation effi   ciency of these polypeptides.
Infl  uence of translation effi  ciency of EBNA1 
and EBNA1𝖫GA on endogenous processing 
of a model CD8+ T cell
The data presented in Fig. 1 provide strong evidence that 
translation effi   ciency of the EBNA1 protein with or without 
its internal GAr domain can directly infl  uence the rate of pro-
duction of RDPs. Since previous studies have proposed that 
the majority of the CD8+ T cell epitopes may be derived from 
RDPs, we designed a series of experiments to determine 
whether increased production of RDPs enhances the presenta-
tion of these epitopes. We assessed the endogenous processing 
and surface presentation of two diff  erent model CD8+ T cell 
epitopes inserted within EBNA1-GFP and EBNA1∆GA-
GFP. These epitopes were the H-2Kb–restricted CTL epitope 
from ovalbumin, SIINFEKL (referred to as SIIN), and the 
HLA B8–restricted CTL epitope, FLRGRAYGL (referred to 
as FLR) from an EBV-encoded EBNA3 pro  tein. In the fi  rst 
set of these experiments H-2Kb–expressing HEK293 cells 
were transiently transfected with either EBNA1-GFP or 
EBNA1∆GA-GFP expression constructs each with or without 
the SIIN epitope. At 48 h after transfection these cells were as-
sessed for cell surface expression of H-2Kb–SIIN complexes 
using a monoclonal antibody (25-D1.16) that recognizes the 
SIIN epitope bound to H-2Kb molecules (21). Representative 
data from one such experiment is presented in Fig. 2 A.
Consistent with the data presented above, a higher level 
of 25-D1.16 antibody binding was observed when these cells 
were transfected with an expression construct encoding 
EBNA1∆GA-GFP compared with EBNA-GFP. To further 
confi  rm these observations using an antigen presentation 
  assay based on CTL recognition, full-length EBNA1 and 
EBNA1∆GA were expressed in an HLA B8-positive human 
keratinocyte (SVMR6) cell line with subsequent assessment 
of CTL lysis of these cells by an FLR-specifi  c CD8+ T cell 
clone, LC13 (22). To ensure that the level of antigen expres-
sion was not limiting, SVMR6 cells were infected with 
  recombinant adenovirus expressing EBNA1 or EBNA1∆GA 
at a multiplicity of infection of 80:1. Data presented in Fig. 2 B 
show that lysis of target cells expressing EBNA1∆GA by 
LC13 T cells was 1.8–2-fold higher compared with the cells 
expressing full-length EBNA1. To further confi  rm this obser-
vation, we tested the endogenous presentation of CD8+ T cell 
epitopes using B cells as antigen-presenting cells. HLA B8-
positive  lymphoblastoid cell line (LCLs) transformed with 
the B95.8 virus (this virus encodes a mutated sequence of the 
FLR epitope) were infected with a recombinant adenovirus 
(MOI 80:1) encoding either EBNA1 or EBNA1∆GA and 
then used as stimulators to activate FLR-specifi  c CD8+ T cell 
responses from an HLA B8 EBV-seropositive individual. 
EBNA1 and EBNA1∆GA include a model FLR epitope 
within the coding sequence. Responder to stimulator ratios 
of 10:1 and 20:1 were used in these assays. The activation of 
FLR-specifi  c T cells was assessed using a combination of 
HLA B8-FLR pentamer and costaining for intracellular IFN-γ 
expression. Representative data from one such experiment 
are presented in Fig. 2 C. These studies showed that IFN-γ 
production by FLR-specifi  c T cells was 1.4–2-fold higher 
when LCLs expressing EBNA1∆GA were used as stimulators. 
The diff  erences in the levels of T cell stimulation were similar 
to the data obtained with cytotoxicity assays (Fig. 2 B).
Endogenous processing of HLA B35-restrcited epitopes 
from recombinant EBV-infected LCLs expressing EBNA1 
and EBNA1𝖫GA
Because most of the data presented in Fig. 2 were based on 
model epitopes inserted into the coding sequence of EBNA1, 
it was important to demonstrate that the eff  ect of protein 
translation can also be observed for an epitope derived from 
EBNA1 itself. To address this issue we constructed a recom-
binant EBV isolate carrying an EBNA1∆GA sequence from 
a B95-8 EBV BAC using lambda red recombinase as previ-
ously described (23). The EBV BAC comprising either full-
length EBNA1 or EBNA1∆GA was transferred into HEK293 
cells, and stable transformants were induced for virus replica-
tion by treatment with phorbol ester, butyrate, and infection 
with a recombinant BZLF1 adenovirus. Viral supernatants 528  PROTEIN TRANSLATION AND CD8+ T CELL EPITOPE PRESENTATION | Tellam et al.
were collected from these transfectants and were used for 
generating two diff  erent sets of LCLs from HLA B35+ indi-
viduals (referred to as D11 and D18). In the fi  rst instance, 
we assessed the expression of EBV latent genes in these 
LCLs  (Fig. 3 A). LCLs expressing full-length EBNA1 or 
EBNA1∆GA showed comparable levels of all EBV latent an-
tigens. To assess the intracellular stability of these latent proteins, 
these LCLs were incubated with cycloheximide (5 μg/ml), 
and the expression of these proteins was assessed after 96 h 
using SDS-PAGE and immunoblotting. As reported previ-
ously, full-length EBNA1 was comparably more stable than 
EBNA1∆GA (13), whereas the other EBV latent proteins 
showed very similar intracellular stabilities.
Having established that these cell lines expressed the full 
complement of EBV latent genes including EBNA1, we next 
assessed the endogenous presentation of an HLA B35-restricted 
CTL epitope (H  P  V  G  E  A  D  Y  F  E  Y  ), which is encoded within 
the EBNA1 sequence (residue number 407–417). A HPV-
specifi  c CTL line was used as eff  ector cells in a standard 51Cr–
release assay. Data presented in Fig. 3 B clearly show that 
LCLs from both D11 and D18 donors, transformed with 
EBV encoding EBNA1∆GA, were recognized by HPV-specifi  c 
CTLs more effi   ciently compared with the paired LCLs carry-
ing the full-length EBNA1 sequence. The diff  erence in the 
level of CTL lysis for both cell lines was almost twofold, 
which was very similar to the levels observed in the earlier 
assays using the FLR-inserted epitope (Fig. 2). To further 
confi  rm these observations we also assessed the endogenous 
presentation of the HPV epitope using an intracellular cyto-
kine assay. HPV-specifi  c T cells were stimulated with D18 
LCLs at diff  erent responder to stimulator ratios, and then the 
cells were assessed for HLA B35-HPV pentamer binding and 
costained for intracellular IFN-γ expression. Data presented 
in Fig. 3 C show that D18 LCLs expressing EBNA1∆GA 
were more effi   cient in inducing IFN-γ expression in HPV-
specifi  c T cells compared with paired LCLs expressing full-
length EBNA1. These data indicate that CTL epitopes 
encoded within EBNA1∆GA are more effi   ciently processed 
and presented through the class I pathway, and this presenta-
tion correlates with the enhanced translation effi   ciency of 
EBNA1∆GA.
Although the data presented in Figs. 2 and 3 indicated 
that translation effi   ciency of target antigens directly impacts 
on the endogenous processing and presentation of CD8+ 
T cell epitopes, it is also possible that the intracellular turnover 
of EBNA1 or EBNA1∆GA may also contribute toward 
  endogenous processing and presentation. Previous studies 
from our laboratory have shown that EBNA1∆GA displays a 
shorter half-life in human B cells compared with full-length 
Figure 2.  Endogenous processing of CD8+ T cell epitopes from 
EBNA1 and EBNA1∆GA. (A) Detection of H-2Kb–SIIN complexes on the 
surface of 293KbC2 cells transfected with constructs expressing EBNA1 or 
EBNA1∆GA. Data shown are the percentage of GFP-positive events (right 
axis) and the relative increase in median fl  uorescence for GFP-positive 
events from transfectants with SIIN-expressing constructs over controls 
without SIIN, with the value for EBNA1∆GA made relative to that for 
EBNA1, which was set to 1 (left axis). (B) CTL recognition of an endog-
enously processed HLA B8-inserted epitope (FLR) in EBNA1 and 
EBNA1∆GA. SVMR6 keratinocytes infected with a recombinant adeno-
virus encoding either EBNA1 (Ad-EBNA1) or EBNA1∆GA (Ad-EBNA1∆GA) 
were used as targets in a standard 51Cr–release assay to assess CTL activ-
ity. An HLA B8-restricted FLR-specifi  c CTL clone, LC13, was used as an 
effector in this assay. The multiplicity of infection was 80:1 for this assay, 
whereas the E to T ratio varied from 20:1 to 0.25:1. These data are repre-
sentative of three separate experiments. (C) Ex vivo stimulation of FLR-
specifi  c CD8+ T cells by EBNA1 and EBNA1∆GA. HLA B8-positive LCLs 
were infected with expression vectors encoding EBNA1-GFP or 
EBNA1∆GA-GFP (both modifi  ed to include FLR encoding sequences; 
see Materials and methods). These cells were used as stimulators to activate 
FLR-specifi  c CD8+ T cells in fresh PBMCs. Responder to stimulator ratios 
of 10:1 and 20:1 were used in this assay. After a 6-h incubation, FLR-
specifi  c CD8+ T cells were assessed for intracellular IFN-γ expression 
  using a Cytofi  x/Cytoperm kit (BD Biosciences).JEM VOL. 204, March 19, 2007  529
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EBNA1. Thus, it is possible that the rapid degradation of 
EBNA1∆GA may also enhance the endogenous presentation 
of the HPV epitope from these homologous proteins. To 
  explore this possibility, we used a modifi  ed ex vivo stimula-
tion assay described for Fig. 3 C. In this experiment, PBMCs 
from an HLA B35+ EBV-seropositive individual were stim-
ulated with MHC–peptide-stripped D11 LCLs (encoding 
  either full-length EBNA1 or EBNA1∆GA) that had been in-
cubated in the presence or absence of cycloheximide to in-
hibit new protein synthesis. These cells were then assessed for 
HLA B35-HPV pentamer binding and costained for intracel-
lular IFN-γ expression. Data presented in Fig. 4 show that 
pretreatment of antigen-presenting cells with citrate buff  er to 
strip MHC–peptide, followed by incubation with cyclohexi-
mide, considerably reduced the proportion of intracellular 
IFN-γ–expressing T cells within the HLA B35-HPV pen-
tamer-positive population by almost 70–80%. In contrast, 
LCLs treated with cycloheximide alone had only a minimal 
eff  ect on the activation of pentamer-positive T cells, whereas 
citric acid treatment showed a diff  erential eff  ect on LCLs ex-
pressing either full-length EBNA1 or EBNA1∆GA which 
correlated with the rate of RDP expression. Pretreatment of 
LCLs with cycloheximide and citric acid had minimal eff  ect 
on the ability of these cells to present synthetic HPV peptide 
(unpublished data). Furthermore, immediate fi  xing of cells 
after cycloheximide treatment showed a similar pattern of T cell 
activation, although IFN-γ expression by these cells was 
  reduced because of the paraformaldehyde treatment of anti-
gen-presenting cells (unpublished data). These observations 
indicate that regardless of the intracellular half-life, the 
  endogenously processed epitopes from EBNA1 and EBNA1∆GA 
proteins are predominantly derived from newly synthesized 
protein. Thus, these results imply that the diff  erence in 
  presentation effi   ciency of CD8+ T cells epitopes from either 
Figure 3.  Endogenous processing of EBNA1 epitopes in B cells 
infected with recombinant EBV. (A) Immunoblot of EBV latent gene 
expression of B cells immortalized with a wild-type EBV BAC (LCL 
wtEBNA1) or an EBV BAC carrying a GAr-deleted EBNA1 (LCL EBNA1∆GA). 
Expression without and after 96 h of cycloheximide treatment is shown. 
EBNA1, EBNA-2, and LMP1 immunoblots were probed with the OTX1, PE2, 
and S12 monoclonal antibodies. EBNA-3 expression was detected with 
EBV immune human sera. (B) CTL recognition of an endogenously proc-
essed HLA B35-restricted epitope (HPV) in LCL wtEBNA1 and LCL 
EBNA1∆GA. LCL’s transformed with recombinant EBV encoding either 
EBNA1 or EBNA1DGA (D18 and D11) were used as targets in a standard 
51Cr–release assay to assess CTL activity. An HLA B35-restricted HPV-specifi  c 
CTL line was used as the effector in this assay. (C) Ex vivo stimulation of 
HPV-specifi  c CD8+ T cells by LCLs transformed with recombinant EBV 
encoding either EBNA1 or EBNA1DGA (D18). These LCLs were used as 
stimulators to activate HPV-specifi  c CD8+ T cells. Responder to stimulator 
ratios of 20:1, 40:1, 80:1, and 160:1 were used in this assay. After a 6-h 
incubation, HPV-specifi  c CD8+ T cells were assessed for intracellular IFN-γ 
expression using a Cytofi  x/Cytoperm kit (BD Biosciences).
Figure 4.  Effect of MHC–peptide stripping and cycloheximide 
treatment on ex vivo intracellular IFN-γ production by specifi  c 
T cells generated to the EBNA1 epitope (H  P  V  G  E  A  D  Y  F  E  Y  ). PBMCs from 
an HLA B35-positive donor were incubated with HLA B35+ve donor LCLs, 
D11 (encoding either full-length EBNA1 or EBNA1∆GA), which had been 
untreated or treated with citrate phosphate (pH 3) buffer, cycloheximide 
(50 μM), or treated with both cycloheximide (50 μM) and citrate buffer. 
Data shown represents the relative HPV pentamer-positive population 
producing IFN-γ.530  PROTEIN TRANSLATION AND CD8+ T CELL EPITOPE PRESENTATION | Tellam et al.
EBNA1 or EBNA1∆GA is primarily determined by their 
translation effi   ciency rather than their intracellular stability.
DISCUSSION
The interaction of the adaptive cellular immune system with 
virus-infected cells determines the outcome of primary viral 
infection. In particular, CD8+ T cells continuously scan the 
surface of virus-infected cells to detect foreign peptides bound 
to MHC class I molecules and eliminate these cells either by 
direct lysis or by secreting cytokines/chemokines which are 
aimed at limiting the replication of the virus (for review see 
references 1, 2). In the face of this hostile eff  ector system, 
  viruses have adopted numerous strategies to evade CD8+ 
T cells (24, 25). This is particularly highlighted in the case of 
persistent viruses like EBV, where the virus selectively sup-
presses the expression of immunodominant antigens (26, 27). 
Although this may be an ideal mechanism for the virus to 
  escape immune recognition, this strategy can also limit their 
capacity to maintain a successful latent infection. To over-
come this dilemma, viruses have evolved strategies to limit 
the availability of the antigen by inhibiting protein translation 
and/or by blocking proteasomal degradation (28). EBV-
encoded EBNA1 is a classic example of a viral protein which 
not only blocks its degradation by proteasomes but also in-
hibits its translation (11, 12). It has been hypothesized that by 
limiting its translation, EBNA1 restricts the generation of 
CD8+ T cell epitopes in virus-infected cells. Recent studies 
have indicated that in spite of this inhibitory eff  ect,  some 
CD8+ T cell epitopes from EBNA1 can be presented on the 
cell surface of EBV-infected B cells (13–15). Extensive analysis 
of the endogenous processing of EBNA1 revealed that these 
epitopes are predominantly generated from DRiPs, which are 
the byproducts of newly synthesized rapidly   degrading poly-
peptides (13). RDPs constitute  30% of the polypeptides syn-
thesized in mammalian cells and degraded by proteasomes 
within 30 min of synthesis (16, 29). The importance of RDPs 
in T cell recognition has also been emphasized in studies based 
on other viral infections and tumor antigens, which also 
showed that endogenously processed CD8+ T cell epitopes 
were generated from newly synthesized proteins rather than 
from the long-lived pool of viral antigens in the cell (30–32).
Considering the importance of RDPs in CD8+ T cell 
recognition, it can be postulated that endogenous processing 
and presentation of MHC class I–restricted epitopes must be 
infl  uenced by the rate at which proteins are synthesized (28). 
Thus, proteins with a slower rate of synthesis may generate 
RDPs less effi     ciently compared with proteins, which are 
more effi   ciently synthesized. Although this hypothesis seems 
quite plausible, there is no evidence demonstrating a direct 
relationship between protein translation, RDPs, and endoge-
nous CD8+ T cell epitope processing. In the present study, 
two homologous viral proteins have been used to demon-
strate the infl  uence of protein translation on CD8+ T cell 
recognition. Comparison of the in vivo translation of EBNA1 
and EBNA1∆GA revealed that these proteins diff  erentially 
expressed RDPs and the degradation of these polypeptides 
could be blocked by the addition of proteasome-specifi  c 
inhibitors. As a consequence, CD8+ T cell epitopes from 
EBNA1∆GA were more effi   ciently processed, and cells ex-
pressing EBNA1∆GA were lysed at higher levels by EBV-
specifi  c CTLs compared with cells expressing poorly translated 
full-length EBNA1. Although this data was generated using a 
GFP tag at the COOH terminus, it would be interesting to 
look for EBNA1 and EBNA1∆GA RDPs with a GFP tag at 
the NH2 terminus. The endogenous processing of CD8+ T cell 
epitopes from EBNA1∆GA is not determined by its intracellu-
lar stability but rather by the rate at which newly synthesized 
polypeptides are produced. Although it is not possible to com-
pletely rule out the possibility that some of the CD8+ T cell ep-
itopes are derived from the degradation of full-length EBNA1 
or EBNA1∆GA protein, it is unlikely that this pathway contrib-
utes substantially toward the overall pool of epitopes. This argu-
ment is based on the observation that blocking new protein 
synthesis after MHC–peptide stripping considerably reduced 
the ex vivo activation potential of antigen-presenting cells.
Collectively the data presented in this study provides evi-
dence linking protein translation and endogenous processing 
of CD8+ T cell epitopes. These observations may have 
  important implications for understanding the hierarchy of 
T cell responses directed toward multiple antigens within a 
complex virus and for designing better therapeutic strategies 
for virus-associated diseases. It is hypothesized that individual 
proteins within a complex virus, which are more effi   ciently 
translated, may provide a larger repertoire of T cell determi-
nants and thus will be more frequently recognized by healthy 
virus carriers. Furthermore, it may be more advantageous 
to design therapeutic strategies that prime T cell responses 
  toward viral proteins more effi   ciently synthesized in human 
cells. Indeed, previous studies by Liu et al. have shown that a 
DNA vaccine based on codon-modifi  ed human papillomavi-
rus type 16 E7, which was expressed at higher levels com-
pared with the wild-type E7, signifi  cantly enhanced CTL 
induction and antitumor activity (33).
MATERIALS AND METHODS
Cell lines. Cell lines were routinely maintained in RPMI 1640 supple-
mented with 2 mM l-glutamine, 100 IU/ml penicillin, and 100 μg/ml 
streptomycin plus 10% FCS (referred to as growth medium). EBV-transformed 
lymphoblastoid cell lines were maintained in growth medium and used as 
targets for various T cell assays. Two diff  erent human epithelial cell lines 
(SVMR6 and HEK 293) (34–36) were used for EBNA1 half-life analysis 
or CTL assays. In addition, HEK293 cells stably expressing the mouse class 
I allele H-2Kb (referred to as 293KbC2) were also used in the study (37).
Generation of recombinant EBV encoding EBNA1 and EBNA1𝖫GA. 
A recombinant EBV encoding EBNA1∆GA was constructed from a B95-8 
EBV BAC using lambda red recombinase as previously described (23). In 
brief, the EBNA1 amino terminus (aa residues 1–327) was fi  rst deleted from 
a wild-type BAC. The truncated EBNA1 was repaired with a DNA frag-
ment containing a chloramphenicol selectable marker at −10 nt relative to 
the EBNA1 translational start site and EBNA1 aa residues 1–89. The chlor-
amphenicol cassette was subsequently removed by the use of Flp recombinase. 
The EBNA1∆GA sequence was confi  rmed by nucleotide sequencing. 
The wild-type B95-8 (encoding full-length EBNA1) or EBNA1∆GA BAC was 
trans  ferred to 293 cells using an auxotrophic, invasive Escherichia coli, and stable JEM VOL. 204, March 19, 2007  531
ARTICLE
transformants were induced for virus replication by treatment with phorbol 
ester, butyrate, and infection with a recombinant BZLF1 adenovirus. Viral 
superna  tants were collected and used to generate LCLs from healthy virus 
carriers (23).
Generation of EBNA1 expression constructs. Full-length EBV-encoded 
EBNA1 and EBNA1∆GA were cloned into the expression vector pcDNA3.1 
(Invitrogen) (34). EBNA1 and EBNA1∆GA sequences were also subcloned 
in-frame with a sequence coding for GFP (pEGFP-N1; Clontech) to generate 
EBNA1-GFP and EBNA1∆GA-GFP. To enable the analysis of endogenous 
processing of these proteins, sequences encoding a previously defi  ned HLA 
B8-restricted, EBNA3 epitope, FLRGRAYGL (referred to as FLR), and a   
H-2Kb–restricted epitope SIINFEKL (referred to as SIIN) were inserted into 
the EBNA1 constructs. The FLR epitope sequence was inserted at the SacII 
site at nucleotide position 1853 of EBNA1, whereas SIIN was inserted into 
EBNA1-GFP constructs between the 3′ end of the EBNA1 sequence and the 
start of the GFP sequence. Recombinant adenovirus encoding EBNA1 and 
EBNA1∆GA were generated by a highly effi   cient, ligation-based protocol of 
Adeno-X System (Clontech) (13, 38).
Pulse–chase experiments for detection of RDPs. For detection of 
EBNA1 RDPs, HeLa cells (2 × 105) were transiently transfected with either 
EBNA1-GFP or EBNA1∆GA-GFP in duplicate. 24 h after transfection the 
cells were incubated at 37°C for 60 min in Met-free medium with the addi-
tion of two proteasome inhibitors, 50 μM MG132 (Merck Biosciences) and 
50 μM lactacystin (Merck Biosciences), for the fi  nal 30 min. The cells were 
then pulsed for 2 min with 100 μCi of [35S]methionine and chased for 0 and 
5 min in growth medium containing 2 mg/ml l-methionine. Cells were 
then lysed in Tris-buff  ered saline including 1% Triton X-100 and protease 
inhibitors, precleared with protein A Sepharose, and lysates were immuno-
precipitated with antibody to GFP (Invitrogen). Immunoprecipitated sam-
ples were subjected to SDS-PAGE and analyzed by autoradiography.
Measurement of EBNA1 and EBNA1𝖫GA protein synthesis. 
HEK293 cells (4 × 105) were transiently transfected with either EBNA1-
GFP or EBNA1∆GA-GFP in duplicate. 24 h after transfection the cells were 
metabolically labeled at 37°C for 12–14 h in growth medium containing 
20 μCi/ml of [3H]methionine (Amersham Biosciences) (20). The cells were 
then washed in phosphate-buff  ered saline and incubated in methionine-free 
growth medium for 30 min at 37°C preceding a 30-min pulse with 100 μCi 
of [35S]methionine (GE Healthcare). After the pulse, cells were lysed in Tris-
buff  ered saline, including 1% Triton X-100 and protease inhibitors, pre-
cleared with protein A Sepharose, and lysates were immunoprecipitated with 
an antibody to GFP (Invitrogen) or a monoclonal antibody to β-tubulin 
(Sigma-Aldrich). Immunoprecipitated samples were added to 10 ml of scin-
tillant fl  uid, Ultima Gold (PerkinElmer) and counted on a Packard Liquid 
Scintillation Analyzer, Tri-carb 2100TR.
In vitro translation assays. EBNA1 and EBNA1∆GA cDNA in 
pcDNA3.1 were transcribed and translated in vitro with T7 RNA polymerase 
using a coupled transcription/translation reticulocyte lysate system (Promega) 
supplemented with 250 μCi of 35[S]-methionine (GE Healthcare). Lysates (5 μl) 
were incubated for 5 min at 95°C with Laemmli sample buff  er (20 μl) and 
subjected to SDS-PAGE. Gels were fi  xed, incubated with Amplify (GE 
Healthcare), dried, and subjected to autoradiography.
Detection of cell surface H-2Kb–SIIN. 293KbC2 cells were transiently 
transfected with EBNA1- and EBNA1∆GA-containing constructs using Li-
pofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. 
For each expression construct, the parent construct without SIIN was used 
as a background control. 48 h after transfection, cells were harvested and 
stained with SIIN–H-2Kb complex–specifi  c mAb 25D1.16 conjugated to 
Alexa Fluor 647 (Invitrogen) (10, 21) (a gift from M. Princiotta and 
J. Yewdell, National Institute of Allergy and Infectious Diseases, Bethesda, 
MD). Cells were washed and analyzed by fl  ow cytometry (FACSCalibur, 
BD Biosciences and Flowjo software, Tree Star Inc.) for GFP expression and 
25D1.16 binding.
In vitro cytotoxicity assays. An EBV-specifi  c CTL clone (LC13) was used 
as an eff  ector in the CTL assays. In some experiments, target cells were trans-
fected with expression vectors encoding EBNA1-GFP or EBNA1∆GA-GFP 
for 36 h or infected with recombinant adenovirus encoding EBNA1 or 
EBNA1∆GA and incubated for 14–16 h at 37°C. After incubation, cells were 
washed in growth medium and labeled with 51Cr for 60 min. After labeling, 
cells were washed with growth medium and used as targets in a 5-h 51Cr–release 
assay (39). These cells were then used as targets in the CTL assay.
Cell surface MHC–peptide stripping and antigen presentation assays. 
Cell surface MHC–peptide stripping and ex vivo antigen presentation assays 
were performed as described previously (34). In brief, HLA B8+ve LCLs were 
infected with recombinant adenovirus encoding EBNA1 or EBNA1∆GA 
and then incubated at 37°C overnight. After incubation, these HLA B8+ve-
transfected LCLs or donor HLA B35+ve LCLs, D11 (encoding either full-
length EBNA1 or EBNA1∆GA) were treated with citrate phosphate (pH3) 
buff  er (0.131 M citric acid, 0.066 M Na2HPO4) for 2 min on ice. The suspen-
sion was then neutralized with a 100-fold dilution of growth medium, and cells 
were washed twice. Aliquots of cells were resuspended in 2 ml growth me-
dium and incubated in the presence or absence of 50 μM cycloheximide for 
5 h. These LCLs were then mixed with peripheral blood mononuclear cells 
from either an HLA B8-positive individual or from an HLA B35-positive 
individual, respectively, at varying responder to stimulator ratios. The   responding 
CD8+ T cells were assessed for intracellular IFN-γ expression using a Cytofi  x/
Cytoperm kit (BD Biosciences).
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